Select Publications
Gerecitano JF et al. A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas. Proc ASCO 2008;Abstract 8512.
Pfreundschuh M et al. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Proc ASCO 2008a;Abstract 8508.
Pfreundschuh M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomized controlled trial (RICOVER-60). Lancet Oncol 2008b;9(2):105-16. Abstract
Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas — First interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Proc ASH 2007;Abstract 385.
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Steven D Gore, MD
- Select publications
Michael J Keating, MB, BS
- Select publications
William I Bensinger, MD
- Select publications
Fredrick B Hagemeister, MD
- Select publications
